Genovis and Promega sign global license agreement and settle litigation

Genovis has reached a settlement in its patent infringement lawsuit with Promega
Corp. and agreed to a royalty bearing, worldwide license to the patents-in-suit.
The settlement ends all ongoing patent-infringement claims between the parties
and Promega has agreed to a royalty bearing, worldwide license to the patents-in
-suit, thereby ending the lawsuit between the parties. The specific terms of the
contract are confidential.

“I am pleased we were able to reach a settlement with a favorable business
solution that accommodates Genovis’ long term growth strategy,” says Fredrik
Olsson, CEO of Genovis.
For more information, please contact: Fredrik Olsson, CEO, Genovis AB Tel: 0046
(0)46 -101233 fredrik.olsson@genovis.com (sarah.fredriksson@genovis.com)
ABOUT GENOVIS

Genovis is a global company that offers enzyme products that facilitate
development and quality control of biologics to customers in the pharmaceutical
and medical technology industries. The Company markets several enzyme products
(“SmartEnzymes”) in innovative product formats all over the world.

The organization consists of Genovis AB and the wholly owned subsidiary Genovis
Inc. in the US. Genovis Inc. handles all sales of enzyme products on the North
American market and Genovis AB handles sales in the rest of the world. Genovis
shares are listed on Nasdaq First North Stockholm and Consensus is the Company’s
Certified Adviser, t: +46(0) 31 745 50 00.